Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 18, 2021- After Review of Approximately 140 patients in ACTIV-3 Critical Care Study, No New Safety Concerns Raised by Independent Data Safety Monitoring Board, Study to Continue Enrollment to Target More than 600 Patients
NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI™ (aviptadil) which is being tested in the ACTIV-3 Critical Care...
-
April 28, 2021
NeuroRx today announces that it has met with Dr. Ekaterine Tikaradze, Minister of Health of Georgia, and other senior leadership, to immediately initiate an Expanded Access Program (EAP) of its...
-
April 26, 2021
Dosing of the first patient in a phase 3 clinical trial of ZYESAMI (aviptadil acetate) was announced by the National Institutes of Health (NIH) last week. The trial, designated as ACTIV-3b:...
-
April 19, 2021
The issues raised by Relief Therapeutics in its release dated April 19, 2021 have no bearing on NeuroRx's ability or commitment to deliver a safe, effective, and stable lifesaving drug on a...
-
April 6, 2021
NeuroRx, Inc. reports today that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health (NIH) as one of two drugs selected for inclusion in a phase III...
-
March 29, 2021
In the news release, NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from...
-
March 26, 2021Results to be Presented at Investor Call on Monday, March 29th at 8:30am EDT
NeuroRx, Inc. announces completion of top line data analysis of the 60-day results in its phase 2b/3 clinical trial, conducted under FDA Fast Track Designation, of ZYESAMI™ (aviptadil acetate)...
-
March 19, 2021
RADNOR, Pa., March 19, 2021 (GLOBE NEWSWIRE) -- NeuroRx, Inc. announced the first patient in its P2/3 study of inhaled ZYESAMI™ in the treatment of moderate and severe COVID-19 (AVICOVID-2) was...
-
March 9, 2021Feasibility work underway to determine the compatibility of NeuroRx's ZYESAMI™ (aviptadil, synthetic VIP) as a dry powder formulation using TFF's Thin-Film Freezing technology
NeuroRx, Inc. and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) are announcing that the companies have entered into a feasibility and material transfer agreement (Feasibility Agreement). Under the...
-
February 23, 2021NeuroRx to File for Emergency Use Authorization in This Patient Population if Positive Results Continue to be Demonstrated at Day-60 Endpoint in Line with FDA's New Guidance
NeuroRx, Inc. announced today that the Phase 2b/3 trial* of ZYESAMI™ (aviptadil, previously RLF-100™) for the treatment of Respiratory Failure in critically ill patients with Covid-19 has...
Click here to view our corporate presentation or on the image below